Form 4: OptiNose Director's Stock Options Converted to Cash and CVRs Following Merger with Paratek Pharmaceuticals

Following the merger of OptiNose with Paratek Pharmaceuticals, a director's stock options were converted into cash and contingent value rights (CVRs) based on the merger agreement.

Summary

• Wilhelmus CM Groenhuyzen, a director of OptiNose, Inc., filed a Form 4 detailing changes in beneficial ownership following the company's merger with Paratek Pharmaceuticals, Inc.
• The merger, effective May 21, 2025, resulted in Orca Merger Sub, Inc. merging with OptiNose, with OptiNose continuing as the surviving entity and a wholly-owned subsidiary of Paratek.
• Each outstanding share of OptiNose common stock was converted into the right to receive $9.00 in cash and one contingent value right (CVR).
• The CVR represents the right to receive up to $5.00 in cash contingent payments upon achievement of specified milestones.
• Outstanding and unexercised stock options were converted into the right to receive cash equal to the excess of $9.00 over the exercise price, if any.
• Stock options with an exercise price greater than $14.00 were canceled for no consideration.
• Stock options with an exercise price between $9.00 and $14.00 were canceled and converted into the right to receive one CVR, with the amount payable reduced by the difference between the exercise price and $9.00.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The merger provides liquidity for shareholders, but the value of the CVR is contingent on future milestones. The cancellation of some stock options without compensation is a negative aspect.

Positives

• Shareholders received $9.00 in cash per share as part of the merger.
• Shareholders have the potential to receive up to $5.00 more per share through the contingent value right (CVR).
• The merger provides liquidity for OptiNose shareholders.

Negatives

• Stock options with exercise prices above $14.00 were canceled without any compensation.
• The additional $5.00 payment per share is contingent on achieving specific milestones, which may not be met.

Risks

• The contingent value rights (CVRs) are subject to the risk that the specified milestones will not be achieved, resulting in no additional payment to holders.
• The success of the merger and integration of OptiNose into Paratek Pharmaceuticals is subject to various risks and uncertainties.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger and the potential for CVR payments.

Industry Context

The pharmaceutical industry is seeing increased merger and acquisition activity as companies look to expand their product pipelines and market share. This merger allows Paratek to acquire OptiNose's assets and potentially leverage its technology.

Comparison to Industry Standards

• Merger valuations in the pharmaceutical industry vary widely depending on the stage of development of the target company's products, market potential, and synergies.
• Contingent value rights (CVRs) are a common tool used in pharmaceutical acquisitions to bridge valuation gaps and align the interests of the buyer and seller around the achievement of specific milestones.
• Comparable transactions would include acquisitions of companies with late-stage clinical assets or approved products in niche markets.

Stakeholder Impact

• Shareholders receive cash and potential future payments through CVRs.
• Employees of OptiNose may experience changes in their roles and responsibilities as the company integrates with Paratek.
• Customers may see changes in product availability and support as a result of the merger.

Next Steps

• Monitor the progress of Paratek Pharmaceuticals in achieving the milestones required for CVR payments.
• Review the terms of the CVR agreement for specific details on the milestones and payment schedule.

Key Dates

Keywords

merger, OptiNose, Paratek Pharmaceuticals, stock options, contingent value right, CVR, Form 4, beneficial ownership, acquisition